MOMENTA PHARMACEUTICALS INC
MOMENTA PHARMACEUTICALS INC (MNTA): 8 pipeline candidates · ~32 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
31.5 months
D/E 0.32 · 0% dilution
Lead: BLA Filed
8 candidates
N/A
N/A
A transparent, data-derived signal for MOMENTA PHARMACEUTICALS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$193.0M
Quarterly Burn
$41.1M
Runway
31.5 mo
Revenue
$6.6M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| biological | Phase 1/Phase 2 |
| intravenous immunoglobulin | Phase 1/Phase 2 |
| m230 | Phase 1 |
| m254 | Phase 1/Phase 2 |
| m267 | Preclinical |
| m281 | Phase 2 |
| m710 | Phase 3 |
| m923 | BLA Filed |
Frequently asked questions
How many drug candidates are in MOMENTA PHARMACEUTICALS INC's pipeline?
MOMENTA PHARMACEUTICALS INC (MNTA) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is MOMENTA PHARMACEUTICALS INC's lead drug candidate?
MOMENTA PHARMACEUTICALS INC's most advanced tracked candidate is biological (Phase 1/Phase 2) for Immune Thrombocytopenic Purpura (ITP).
What is MOMENTA PHARMACEUTICALS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, MOMENTA PHARMACEUTICALS INC has approximately 31.5 months of cash runway.
Who is the CEO of MOMENTA PHARMACEUTICALS INC?
Craig A. Wheeler is the chief executive officer of MOMENTA PHARMACEUTICALS INC (MNTA).
Get the full picture on MOMENTA PHARMACEUTICALS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.